Greg Cima

The firm received FDA 510(k) clearance late last year for its 10-minute blood-based test that stratifies patients by their risk of developing sepsis.

The agency is cross-training employees to add surge capacity in response to shifting demand and is helping develop a pending national testing plan.

The firm plans to file for regulatory approval of its first test, a chemiluminescent ELISA for respiratory disease, as early as the first quarter of 2024.

The firm reported Thursday its Q1 revenues declined 30 percent as COVID-19 revenues dwindled but non-COVID organic revenues grew 6 percent.

The firm reported revenues were down 2 percent for the quarter year over year despite growth in its imaging, Varian, and advanced therapies businesses.

The Massachusetts-based startup aims to advance testing for parasitic and viral diseases including Chagas, Zika, and Lyme, and tapeworm and liver fluke infections.

The Industrial Participant Program, part of the Wyss Diagnostics Accelerator, provides a hub for collaboration and guidance to move promising tech forward.

The firm posted 20 percent organic growth excluding COVID-19-related income and is eyeing potential M&A deals that could "bulk up" its existing businesses.

The biotech subsidiary of semiconductor maker Qorvo hopes to emerge as the point-of-care instrument maker of choice for pharmacies, physicians, and care facilities.

The firm said its machine learning-based AudibleHealth AI platform will undergo testing ahead of an anticipated regulatory filing by the end of this year.